{ "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-12T10:31:24Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 24.1, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a0952a-c7e5-75c2-9bde-f530d14068d0\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: interferon Alfa-2b, Recombinant\nSense to describe: (none recorded)\nDomain code: PHY.MAT\nAlso known as: (none)\n\n\nContext for this batch of 1001 things:\n#", "usd": 0.0, "recall": true }, "codex": { "seconds": 81.2, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a0952a-c7dc-7011-8676-eabd166880fd\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: interferon Alfa-2b, Recombinant\nRegistry id: vr.tr.interferon-alfa-2b-recombinant\nPlane / domain: PHY / PHY.MAT\nRegistry definition: (none recorded)\n" } }, "enrichment": { "pass": 3, "engine": "claude", "producedAt": "2026-10-06T12:00:00Z", "ingestedAt": "2026-10-06T08:48:47+00:00", "fields": [ "agent_conduct", "ethics", "failure_modes_and_hazards", "owners", "standards_and_regulation", "visual_identification" ] }, "gate": { "passed": true, "version": "1.0", "at": "2026-10-07T10:10:31+00:00", "evidence": [ "completeness 1.00", "sense: Wikidata description", "2 live sources", "review by codex: pass" ] } }, "metaModel": { "id": "THING-Q4391540", "registryId": "vr.tr.interferon-alfa-2b-recombinant", "name": "interferon Alfa-2b, Recombinant", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.MAT" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q4391540/", "model": { "registry_id": "vr.tr.interferon-alfa-2b-recombinant", "name": "interferon Alfa-2b, Recombinant", "purpose": "Enable an AI agent to recognize recombinant interferon alfa-2b, assess the identity and functional quality of a material lot, and determine which handling or use decisions its evidence supports.", "definition": "Recombinant interferon alfa-2b is a biotechnology-produced form of the human type I interferon alfa-2b protein that activates interferon receptors and induces antiviral, antiproliferative and immunomodulatory responses.", "scope_statement": "This PHY / PHY.MAT model owns the recombinant interferon alfa-2b substance registered as vr.tr.interferon-alfa-2b-recombinant, including molecular identity, production provenance, biological potency, impurities, stability and material-use constraints.", "in_scope": [ "Reference protein identity and evidence distinguishing alfa-2b from other interferons", "Recombinant origin, manufacturer and material-lot traceability", "Protein content, biological potency and assay comparability", "Structural integrity, aggregation and process-related impurities", "Material presentation, storage history and suitability for a specified use" ], "out_of_scope": [ "The IFNA2 gene and its biological regulation", "Endogenous interferon production and whole immune-system behavior", "Pegylated interferon alfa-2b, fusion proteins and other modified derivatives as separate substances", "Finished medicinal-product formulations, packaging and administration devices", "Manufacturing-process design and facility operation", "Patient-specific prescribing, dosing and treatment monitoring" ], "distinguishing_features": [ "Require sequence-level evidence matching an authoritative alfa-2b reference; an alpha-interferon activity result alone cannot establish the subtype.", "Require recombinant-production provenance to distinguish the material from naturally isolated interferon with a matching protein sequence.", "Use the non-glycosylated recombinant protein as the identity baseline, while recording any detected molecular modifications. [NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/recombinant-interferon-alfa-2b)", "Check for covalent PEG, fusion partners or engineered extensions before mapping a material to this unmodified-substance entry.", "Distinguish the active protein from branded medicines and their excipients; INTRON A documentation describes a recombinant protein of approximately 19.3 kDa produced using E. coli. [DailyMed label](https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setId=fd653d74-48ab-49e4-a42d-ec1cbc59badb)" ], "characteristics": [ { "name": "Reference sequence match", "kind": "relation", "unit_or_values": "Versioned reference sequence, residue numbering convention, analytical method and observed differences", "why_it_matters": "Establishes alfa-2b identity without confusing related interferon subtypes." }, { "name": "Recombinant expression origin", "kind": "relation", "unit_or_values": "Expression host, construct reference, producer and lot-linked evidence", "why_it_matters": "Establishes recombinant provenance and informs which process impurities require assessment." }, { "name": "Molecular modification status", "kind": "category", "unit_or_values": "Reference-compatible; glycosylated; PEG-conjugated; fused or extended; other modification; unresolved", "why_it_matters": "Separates this substance from derivatives and identifies deviations needing investigation." }, { "name": "Measured molecular mass", "kind": "measurement", "unit_or_values": "Da, with analytical method and molecular species assignment", "why_it_matters": "Supports identity and detection of truncation or modification without treating nominal mass as sufficient proof." }, { "name": "Protein concentration", "kind": "measurement", "unit_or_values": "mg/mL, with method and distinction between interferon content and total protein", "why_it_matters": "Prevents carrier proteins or impurities from being counted as active interferon." }, { "name": "Biological potency", "kind": "measurement", "unit_or_values": "IU/mL or IU per material unit, with assay, reference standard and uncertainty", "why_it_matters": "Records functional activity separately from protein mass." }, { "name": "Specific activity", "kind": "measurement", "unit_or_values": "IU/mg interferon protein, with linked potency and protein-content methods", "why_it_matters": "Allows qualified comparison of activity relative to material quantity." }, { "name": "Protein integrity profile", "kind": "measurement", "unit_or_values": "Percent monomer, aggregates, fragments and modified species, each with method", "why_it_matters": "Reveals deterioration or heterogeneity that an identity label can conceal." }, { "name": "Process impurity burden", "kind": "measurement", "unit_or_values": "Host-cell protein in ng/mg, residual DNA in ng/mg and endotoxin in EU/mg or EU/mL, with detection limits", "why_it_matters": "Supports lot suitability assessment using limits appropriate to its intended use." }, { "name": "Physical presentation and matrix", "kind": "state", "unit_or_values": "Solution or dried preparation; buffer identity; pH; relevant matrix components", "why_it_matters": "Makes stability and analytical results interpretable for the actual material." }, { "name": "Storage and excursion history", "kind": "state", "unit_or_values": "Temperature in degrees Celsius, duration, freeze-thaw count and documented excursions", "why_it_matters": "Connects handling history to evidence for retained integrity and potency." }, { "name": "Use qualification", "kind": "state", "unit_or_values": "Research use; qualified manufacturing input; reference material; quarantined; rejected; unresolved", "why_it_matters": "Prevents molecular identity alone from being treated as authorization for a particular use." } ], "affordances": [ "Match a material record to the alfa-2b reference and flag subtype or derivative mismatches.", "Trace a lot to recombinant-production evidence and its certificate of analysis.", "Compare protein content and potency only when assay methods and reference standards support comparison.", "Evaluate aggregation, degradation and process impurities against a specified material-use specification.", "Select documented storage or preparation conditions for the actual presentation.", "Flag a lot for quarantine or further testing when identity, stability or use-qualification evidence is insufficient." ], "agent_conduct": { "may": [ "Describe recombinant interferon alfa-2b and its approved uses from regulatory sources.", "Track storage, cold chain and expiry of stock on a pharmacy's instructions." ], "must_not": [ "Recommend, prescribe or adjust a dose for a person.", "Present it as a cure for diseases it is not approved to treat.", "Supply it outside the regulated prescription chain.", "Hide or downplay reported serious side effects such as severe depression." ], "requires_human": [ "Starting, stopping or changing a person's treatment with it." ] }, "ethics": { "considerations": [ "It can cause serious psychiatric and other side effects that need medical monitoring.", "Access to costly biological medicines is unequal between countries and patients." ], "affected_parties": [ "Patients and their families", "Prescribers and pharmacists" ] }, "owners": { "steward": "The marketing authorization holder; medicines regulators and prescribers control its use.", "master_systems": [ "Medicines regulators' product registers" ] }, "visual_identification": [ "Supplied as a sterile solution or powder in vials, pens or prefilled syringes.", "Identified by the product label and batch, not by appearance." ], "failure_modes_and_hazards": [ "Can cause depression, suicidal thoughts and other serious adverse effects.", "Loss of cold chain can make the product ineffective." ], "standards_and_regulation": [ "European Pharmacopoeia monograph on interferon alfa-2 concentrated solution, European Directorate for the Quality of Medicines and HealthCare." ], "what_it_is_for": [ "Recombinant interferon alfa-2b is used in prescription medicines for selected viral infections and cancers, with indications depending on the authorised product and jurisdiction.", "It is encountered in biopharmaceutical manufacturing and quality control, where protein identity, purity and biological activity are assessed.", "Research laboratories also use it to study interferon signalling and cellular antiviral responses." ] }, "sources": [ { "id": "wikidata", "title": "Wikidata item Q4391540: interferon Alfa-2b, Recombinant", "url": "https://www.wikidata.org/wiki/Q4391540", "url_status": "live", "what_it_supports": "identity and sense of the item", "checked_by": "wikidata-api" }, { "id": "wikipedia-en", "title": "Wikipedia: Interferon alfa-2b", "url": "https://en.wikipedia.org/wiki/Interferon_alfa-2b", "url_status": "live", "what_it_supports": "general description of the item", "checked_by": "wikidata-api sitelink" } ], "structure": { "bundles": [ { "id": "alfa-2b-molecular-identity", "name": "Alfa-2b molecular identity", "description": "Establish the protein subtype and the boundary between this substance and related interferon materials.", "rationale": "Interferon naming and biological activity alone do not uniquely establish recombinant alfa-2b identity.", "layers": [ { "id": "sequence-and-protein-form", "name": "Sequence and protein form", "description": "Anchor material identity to an explicit mature-protein reference.", "findings": [ { "id": "subtype-confirmation", "name": "Subtype confirmation", "description": "Require a versioned sequence reference and analytical evidence capable of resolving alfa-2b from closely related subtypes.", "questions": [ { "text": "Which authoritative mature-protein sequence and numbering convention define alfa-2b for this material?", "kind": "definition", "id": "subtype-confirmation-q01" }, { "text": "Which peptide-mapping or sequencing results distinguish this lot from alfa-2a and other alpha interferons?", "kind": "measurement", "id": "subtype-confirmation-q02" } ] } ] }, { "id": "derivative-and-product-boundaries", "name": "Derivative and product boundaries", "description": "Separate the recombinant protein from conjugates, engineered constructs and preparations containing it.", "findings": [ { "id": "unmodified-substance-boundary", "name": "Unmodified substance boundary", "description": "Record covalent modifications and preparation components without silently treating a derivative or finished medicine as the base substance.", "questions": [ { "text": "Does the material contain covalent PEG, a fusion partner, an affinity tag or another engineered extension?", "kind": "boundary", "id": "unmodified-substance-boundary-q01" }, { "text": "Does the supplied name identify the protein itself, a formulated medicine or a research preparation containing the protein?", "kind": "boundary", "id": "unmodified-substance-boundary-q02" } ] } ] } ] }, { "id": "recombinant-origin-and-lot-quality", "name": "Recombinant origin and lot quality", "description": "Connect each material lot to its recombinant origin and impurity evidence.", "rationale": "Sequence identity cannot establish production origin or the quality of a particular lot.", "layers": [ { "id": "expression-provenance", "name": "Expression provenance", "description": "Record the evidence supporting recombinant origin and producer continuity.", "findings": [ { "id": "host-and-lot-traceability", "name": "Host and lot traceability", "description": "Link host and construct information to the material actually received rather than assuming every supplier follows a branded product's process.", "questions": [ { "text": "Which producer records establish the expression host and recombinant construct for this material?", "kind": "provenance", "id": "host-and-lot-traceability-q01" }, { "text": "How are the received lot, original manufacturing lot and certificate of analysis linked?", "kind": "provenance", "id": "host-and-lot-traceability-q02" } ] } ] }, { "id": "process-residues", "name": "Process residues", "description": "Assess contaminants arising from the documented expression and purification system.", "findings": [ { "id": "residual-contaminant-profile", "name": "Residual contaminant profile", "description": "Require relevant impurity measurements and use-specific limits, including host-derived residues and endotoxin where applicable.", "questions": [ { "text": "What host-cell protein, residual DNA, endotoxin and relevant process-residue results are available, with methods and detection limits?", "kind": "measurement", "id": "residual-contaminant-profile-q01" }, { "text": "Which intended-use specification governs acceptance, and what action follows an absent or failing result?", "kind": "action", "id": "residual-contaminant-profile-q02" } ] } ] } ] }, { "id": "interferon-potency-and-assay-meaning", "name": "Interferon potency and assay meaning", "description": "Represent functional activity with the experimental context needed to interpret it.", "rationale": "Protein quantity and interferon activity are different measurements, and activity values require reference-standard traceability.", "layers": [ { "id": "functional-readout", "name": "Functional readout", "description": "Identify which interferon response the assay measures.", "findings": [ { "id": "response-assay-context", "name": "Response assay context", "description": "Alpha interferons produce receptor-mediated antiviral, antiproliferative and immune-modulating effects; record the particular response measured rather than treating these endpoints as interchangeable. [NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/recombinant-interferon-alfa-2b)", "questions": [ { "text": "Does the assay measure antiviral protection, a signaling reporter, proliferation or another defined response?", "kind": "definition", "id": "response-assay-context-q01" }, { "text": "Which cell system, challenge conditions, controls and response endpoint determine the measured activity?", "kind": "measurement", "id": "response-assay-context-q02" } ] } ] }, { "id": "units-and-comparability", "name": "Units and comparability", "description": "Connect reported activity to calibration and protein-content evidence.", "findings": [ { "id": "potency-standard-traceability", "name": "Potency standard traceability", "description": "Treat IU values and specific activity as calibrated results with defined denominators, rather than universal mass conversions.", "questions": [ { "text": "Which reference standard, assigned potency and calibration procedure support the reported IU value?", "kind": "provenance", "id": "potency-standard-traceability-q01" }, { "text": "Does the mass denominator measure interferon specifically, and what uncertainty applies to the resulting IU/mg?", "kind": "measurement", "id": "potency-standard-traceability-q02" }, { "text": "What bridging evidence permits comparison with results from another laboratory, assay or standard?", "kind": "boundary", "id": "potency-standard-traceability-q03" } ] } ] } ] }, { "id": "protein-integrity-and-stability", "name": "Protein integrity and stability", "description": "Assess whether the material retains its relevant structure and activity through storage and preparation.", "rationale": "A correctly named lot may become unsuitable through aggregation, modification or activity loss.", "layers": [ { "id": "structural-quality", "name": "Structural quality", "description": "Record protein species and evidence of structural integrity.", "findings": [ { "id": "intact-and-altered-species", "name": "Intact and altered species", "description": "Distinguish intended protein from aggregates, fragments and chemically altered forms using methods appropriate to each attribute.", "questions": [ { "text": "What measurements quantify monomer, aggregates, fragments and modified protein species?", "kind": "measurement", "id": "intact-and-altered-species-q01" }, { "text": "What evidence supports the expected folding and disulfide pattern, and how does it relate to measured potency?", "kind": "measurement", "id": "intact-and-altered-species-q02" } ] } ] }, { "id": "presentation-dependent-stability", "name": "Presentation-dependent stability", "description": "Tie stability conclusions to matrix, container and handling history.", "findings": [ { "id": "validated-handling-window", "name": "Validated handling window", "description": "Record the actual solution or dried presentation and its supported handling limits without transferring another formulation's shelf life.", "questions": [ { "text": "Which buffer, pH, protein concentration, container and physical presentation were covered by the stability evidence?", "kind": "provenance", "id": "validated-handling-window-q01" }, { "text": "What storage temperatures, preparation hold times and freeze-thaw limits are supported for this material?", "kind": "measurement", "id": "validated-handling-window-q02" }, { "text": "What assessment or retesting is required after a documented excursion?", "kind": "action", "id": "validated-handling-window-q03" } ] } ] } ] }, { "id": "material-use-and-regulatory-identity", "name": "Material use and regulatory identity", "description": "Connect verified substance identity and lot evidence to a bounded use decision.", "rationale": "Research preparations, manufacturing inputs and medicinal products can share an ingredient name while requiring different evidence.", "layers": [ { "id": "identifier-and-grade-mapping", "name": "Identifier and grade mapping", "description": "Resolve external identifiers and determine which material qualification they actually support.", "findings": [ { "id": "identifier-scope-and-use-status", "name": "Identifier scope and use status", "description": "Verify identifier scope and grade documentation independently of supplier naming or brand association.", "questions": [ { "text": "Which CAS, UNII, pharmacopoeial or other authoritative identifiers resolve specifically to this recombinant substance rather than a derivative or formulation?", "kind": "definition", "id": "identifier-scope-and-use-status-q01" }, { "text": "Which documents qualify this lot for its proposed research, reference-standard or manufacturing role?", "kind": "provenance", "id": "identifier-scope-and-use-status-q02" }, { "text": "Which jurisdiction-specific product authorization belongs to a linked medicinal-product record rather than to this substance?", "kind": "boundary", "id": "identifier-scope-and-use-status-q03" } ] } ] }, { "id": "handling-and-disposition", "name": "Handling and disposition", "description": "Determine permitted material actions using relevant safety and quality evidence.", "findings": [ { "id": "evidence-based-material-disposition", "name": "Evidence-based material disposition", "description": "Separate occupational handling information from medicinal-product warnings and base disposition on the actual preparation and intended use.", "questions": [ { "text": "Which current safety data sheet and local requirements apply to the supplied preparation, including any assigned GHS classification or exposure limit?", "kind": "provenance", "id": "evidence-based-material-disposition-q01" }, { "text": "Do identity, potency, impurities and handling history support use, further testing, quarantine or rejection against the applicable specification?", "kind": "action", "id": "evidence-based-material-disposition-q02" }, { "text": "Which handling and disposal controls apply to this protein preparation and its matrix components?", "kind": "action", "id": "evidence-based-material-disposition-q03" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "This is recall-based information; no sources were consulted.", "Clinical uses listed include historical uses and do not establish current approval, availability or preferred treatment.", "Exact chemical registry identifiers, applicable pharmacopoeial monographs, purity specifications and storage limits require verification for the relevant material or product." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of interferon Alfa-2b, Recombinant this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "scheme": "International Nonproprietary Name (INN)", "value_or_pattern": "interferon alfa-2b", "note": "Uses the spelling 'alfa'; recombinant describes the production origin." }, { "scheme": "WHO Anatomical Therapeutic Chemical (ATC) classification", "value_or_pattern": "L03AB05", "note": "Classifies interferon alfa-2b as a medicine rather than identifying a particular formulation or manufacturing process." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of interferon Alfa-2b, Recombinant this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Treatment of chronic hepatitis B in selected clinical settings.", "Historical treatment of chronic hepatitis C, including combination therapy with ribavirin.", "Treatment of selected malignancies, including hairy cell leukemia and melanoma.", "Laboratory studies of type I interferon signaling and antiviral responses." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of interferon Alfa-2b, Recombinant this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-measurements", "name": "Typical measurements", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "quantity": "Polypeptide length", "typical_range": "165", "unit": "amino acid residues" }, { "quantity": "Molecular mass of the unmodified protein", "typical_range": "approximately 19.2", "unit": "kDa" }, { "quantity": "Biological activity", "typical_range": "Preparation-dependent; determined by a calibrated biological assay", "unit": "IU" } ], "questions": [ { "id": "evidence-measurements-q01", "text": "Which of these typical measurements hold for the sense of interferon Alfa-2b, Recombinant this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Protein aggregation, denaturation or adsorption to surfaces can reduce usable biological activity.", "Therapeutic administration can cause flu-like symptoms and fatigue.", "Serious neuropsychiatric effects, including depression and suicidal behavior, can occur.", "Bone marrow suppression can produce clinically significant cytopenias.", "Treatment can provoke or exacerbate autoimmune disease and can cause hepatic toxicity." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of interferon Alfa-2b, Recombinant this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-regional-variation", "name": "Regional variation", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Approved indications, available formulations and marketing status vary by jurisdiction and product." ], "questions": [ { "id": "evidence-regional-variation-q01", "text": "Which of these regional variation hold for the sense of interferon Alfa-2b, Recombinant this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "Interferon alfa-2a", "difference": "A closely related protein with lysine at residue 23, whereas interferon alfa-2b has arginine at that position." }, { "name": "Peginterferon alfa-2b", "difference": "Interferon alfa-2b covalently modified with polyethylene glycol, altering its pharmacokinetics." }, { "name": "Human interferon alfa-2b of natural origin", "difference": "Distinguished by production origin; recombinant material is produced through an engineered expression system." }, { "name": "Interferon alfa-2b medicinal product", "difference": "A finished product contains the active protein in a specified formulation, concentration and delivery presentation." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of interferon Alfa-2b, Recombinant this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Which authoritative mature alfa-2b sequence, subtype-discriminating residues and disulfide reference should anchor identity verification?", "Which CAS, UNII and other identifier records unambiguously cover the recombinant unmodified substance, and are any commonly returned database records misassigned?", "Which potency reference standards and assay-bridging evidence support comparison across suppliers and laboratories?", "Which lot-specific limits for aggregates, modified species, host-derived impurities and endotoxin apply to each intended material use?", "Which preparation-specific stability studies, safety classifications and current jurisdictional records support handling and use decisions?" ], "statistics": { "bundles": 6, "layers": 11, "findings": 17, "questions": 31 } }